Scilex Holding Company shares climbed 7% on Monday after the company announced it had signed a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based private investment firm iHolding Group LLP. Under the proposed agreement, iHolding would acquire approximately 6.7 million newly issued Scilex common shares at $15.00 per share. The investment would provide additional capital to support Scilex's long-term expansion strategy across healthcare and medical technology, including product development, commercialization activities, acquisitions, and general working capital requirements. The transaction remains subject to customary closing conditions, including due diligence, negotiation and execution of definitive agreements, board approvals, shareholder approval, and any necessary regulatory clearances. Scilex specializes in non-opioid therapies for acute and chronic pain, and the proposed financing would represent one of the largest healthcare investments from Kazakhstan into a U.S.-listed biopharmaceutical company in recent years.
Scilex Holding CompanySecured $100M strategic investment proposal providing capital for expansion